Literature DB >> 21977165

B-Type Natriuretic Peptide (BNP) and Left Ventricular (LV) Function in Patients with ST-Segment Elevation Myocardial Infarction (STEMI).

Maria Dorobantu1, Ana-Gabriela Fruntelata, Alexandru Scafa-Udriste, Oana-Florentina Tautu.   

Abstract

BACKGROUND: After acute myocardial infarction (AMI), left ventricular (LV) function is a well-established prognostic marker. Recent studies indicate that serum levels of brain natriuretic peptide (BNP) also represent an prognostic marker in this setting but so far without a precise cut-off value.
OBJECTIVE: The aim of this study was to assess the predictive value of BNP serum levels for LV function assessed by echocardiography in STEMI patients undergoing revascularization.
METHODS: We prospectively studied a cohort of 88 consecutive patients (mean age 51.6 years, 88.6% males) hospitalized in our clinic for STEMI in Killip class I (50% anterior infarction), who underwent reperfusion therapy. Serum BNP levels were measured on admission, at 24h and at 30 days after reperfusion. Detailed echocardiography was performed at baseline, at 24 hours after reperfusion, on discharge and at follow-up at 1 month. Left ventricular systolic and diastolic dysfunction were defined by LVEF < 45% and E/A ratio respectively.
RESULTS: ROC curve analysis showed that BNP measurements on admission and at 24 hours after revascularization have no predictive value neighter for diastolic LV dysfunction in anteior or inferior AMI patients, nor for systolic LV dysfunction in inferior AMI patients. Only BNP levels at 24 hours after revascularization can predict systolic LV dysfunction in anterior AMI patients with a 90.3% sensitivity and a 60% false positive rate at a cutt off value of 90pg/ml.
CONCLUSIONS: Early measurement of BNP levels may allow early prediction of anterior STEMI patients at risk of developing systolic LV dysfunction after revascularization therapy.

Entities:  

Keywords:  LV dysfunction; brain natriuretic peptide (BNP); myocardial infarction; revascularization

Year:  2010        PMID: 21977165      PMCID: PMC3152842     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  24 in total

1.  N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes.

Authors:  Marcello Galvani; Filippo Ottani; Luigi Oltrona; Diego Ardissino; Gian Franco Gensini; Aldo P Maggioni; Pier Mannuccio Mannucci; Nicola Mininni; Maria Domenica Prando; Marco Tubaro; Arialdo Vernocchi; Carlo Vecchio
Journal:  Circulation       Date:  2004-06-14       Impact factor: 29.690

2.  Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty.

Authors:  J Tateishi; M Masutani; M Ohyanagi; T Iwasaki
Journal:  Clin Cardiol       Date:  2000-10       Impact factor: 2.882

3.  Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length.

Authors:  S Wiese; T Breyer; A Dragu; R Wakili; T Burkard; S Schmidt-Schweda; E M Füchtbauer; U Dohrmann; F Beyersdorf; D Radicke; C J Holubarsch
Journal:  Circulation       Date:  2000-12-19       Impact factor: 29.690

4.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

Authors:  J A de Lemos; D A Morrow; J H Bentley; T Omland; M S Sabatine; C H McCabe; C Hall; C P Cannon; E Braunwald
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

5.  Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty.

Authors:  Z S Kyriakides; M Markianos; L Michalis; A Antoniadis; N I Nikolaou; D T Kremastinos
Journal:  Clin Cardiol       Date:  2000-04       Impact factor: 2.882

6.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

Authors:  Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough
Journal:  N Engl J Med       Date:  2002-07-18       Impact factor: 91.245

7.  Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators.

Authors:  C Hall; C P Cannon; S Forman; E Braunwald
Journal:  J Am Coll Cardiol       Date:  1995-11-15       Impact factor: 24.094

8.  N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.

Authors:  Stefan K James; Bertil Lindahl; Agneta Siegbahn; Mats Stridsberg; Per Venge; Paul Armstrong; Elliot S Barnathan; Robert Califf; Eric J Topol; Maarten L Simoons; Lars Wallentin
Journal:  Circulation       Date:  2003-07-07       Impact factor: 29.690

9.  Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis.

Authors:  Satoru Suzuki; Michihiro Yoshimura; Masafumi Nakayama; Yuji Mizuno; Eisaku Harada; Teruhiko Ito; Shota Nakamura; Koji Abe; Megumi Yamamuro; Tomohiro Sakamoto; Yoshihiko Saito; Kazuwa Nakao; Hirofumi Yasue; Hisao Ogawa
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

10.  B-type natriuretic peptide in cardiovascular disease.

Authors:  James A de Lemos; Darren K McGuire; Mark H Drazner
Journal:  Lancet       Date:  2003-07-26       Impact factor: 79.321

View more
  1 in total

1.  Predictors of Left Ventricle Remodeling: Combined Plasma B-type Natriuretic Peptide Decreasing Ratio and Peak Creatine Kinase-MB.

Authors:  Jen-Te Hsu; Chang-Min Chung; Chi-Ming Chu; Yu-Shen Lin; Kuo-Li Pan; Jung-Jung Chang; Po-Chang Wang; Shih-Tai Chang; Teng-Yao Yang; Shih-Jung Jang; Tsung-Han Yang; Ju-Feng Hsiao
Journal:  Int J Med Sci       Date:  2017-01-15       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.